Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

15.74
-0.4800-2.96%
Pre-market: 15.750.0100+0.06%07:04 EDT
Volume:1.22M
Turnover:19.22M
Market Cap:2.17B
PE:-13.85
High:16.11
Open:15.62
Low:15.54
Close:16.22
Loading ...

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

PR Newswire
·
23 Jan

Guidewire to replace Arrowhead in S&P 400 index at open on 1/27

TIPRANKS
·
23 Jan

S&P Dow Jones Indices: Arrowhead Pharmaceuticals Will Replace Barnes Group Inc. in S&P Smallcap 600

THOMSON REUTERS
·
23 Jan

Arrowhead Pharmaceuticals' New Drug Application for Plozasiran Accepted by FDA

MT Newswires Live
·
18 Jan

FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease Treatment

Dow Jones
·
18 Jan

Arrowhead says FDA accepts NDA for investigational plozasiran

TIPRANKS
·
18 Jan

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

THOMSON REUTERS
·
18 Jan

Arrowhead Pharmaceuticals Inc - FDA Sets Pdufa Date for Plozasiran as November 18, 2025

THOMSON REUTERS
·
18 Jan

Arrowhead Pharmaceuticals: Strong Growth Potential Backed by siRNA Therapeutics and Financial Stability

TIPRANKS
·
03 Jan

Arrowhead Pharmaceuticals Doses First Patients in Trial of Potential Obesity Drug

MT Newswires Live
·
23 Dec 2024

Arrowhead doses 1st patients in study of ARO-INHBE for obesity treatment

TIPRANKS
·
23 Dec 2024

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Inhbe for the Treatment of Obesity

THOMSON REUTERS
·
23 Dec 2024

Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Dec 2024

Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
20 Dec 2024

B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating

MT Newswires Live
·
12 Dec 2024

Arrowhead Pharmaceuticals: Positioned for Growth with Strategic Partnerships and siRNA Advancements

TIPRANKS
·
12 Dec 2024

Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
12 Dec 2024

Promising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy Rating

TIPRANKS
·
12 Dec 2024

Arrowhead announces interim results from ARO-CFB study

TIPRANKS
·
11 Dec 2024